Treatment of NSCLC cells with Bcl-2 antagonist alone resulted in increased expression of Mcl-1, whereas Mcl-1 expression was markedly reduced following combined treatment with harmine and either ABT-737 or ABT-199. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.